Swedbank AB grew its stake in shares of Solventum Co. (NYSE:SOLV - Free Report) by 20.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 107,197 shares of the company's stock after buying an additional 18,108 shares during the period. Swedbank AB owned 0.06% of Solventum worth $7,474,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of SOLV. Davis Selected Advisers purchased a new position in Solventum during the second quarter valued at approximately $273,070,000. Nuance Investments LLC purchased a new position in shares of Solventum during the 2nd quarter valued at $115,829,000. Newport Trust Company LLC bought a new position in shares of Solventum in the second quarter worth $98,976,000. Baupost Group LLC MA purchased a new stake in shares of Solventum in the second quarter worth $96,242,000. Finally, Magnetar Financial LLC boosted its stake in Solventum by 2,880.8% during the second quarter. Magnetar Financial LLC now owns 1,490,410 shares of the company's stock valued at $78,813,000 after buying an additional 1,440,410 shares during the period.
Shares of NYSE:SOLV opened at $71.50 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company's fifty day moving average is $70.51 and its 200 day moving average is $62.40. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $96.05.
A number of equities analysts have weighed in on SOLV shares. Morgan Stanley upped their target price on Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a research note on Monday, November 11th. Stifel Nicolaus initiated coverage on shares of Solventum in a research report on Tuesday, October 8th. They issued a "buy" rating and a $82.00 price objective on the stock. Piper Sandler lifted their target price on shares of Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a research report on Friday, November 8th. The Goldman Sachs Group increased their price target on shares of Solventum from $48.00 to $54.00 and gave the stock a "sell" rating in a report on Monday, August 12th. Finally, BTIG Research assumed coverage on shares of Solventum in a report on Thursday, September 5th. They set a "neutral" rating for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $68.00.
Check Out Our Latest Report on SOLV
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.